Skip Navigation



Hum. Reprod. Advance Access published online on April 22, 2004
Human Reproduction, doi:10.1093/humrep/deh231
© 2004 by European Society of Human Reproduction and Embryology
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/6/1418    most recent
deh231v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Eberhard, J.
Right arrow Articles by Giwercman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eberhard, J.
Right arrow Articles by Giwercman, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received December 18, 2003
Accepted February 10, 2004

Article

Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study

J. Eberhard 1*, O. Ståhl 1, Y. Giwercman 2, M. Cwikiel 3, E. Cavallin-Ståhl 3, K.B. Lundin 4, P. Flodgren 3, A. Giwercman 5

1 Fertility Center, Malmö University Hospital, Lund University, Malmö, Sweden; Department of Oncology, Lund University Hospital, Lund University, Lund, Sweden
2 Department of Urology, Malmö University Hospital, Lund University, Malmö, Sweden
3 Department of Oncology, Lund University Hospital, Lund University, Lund, Sweden
4 Fertility Center, Malmö University Hospital, Lund University, Malmö, Sweden; Department of Urology, Malmö University Hospital, Lund University, Malmö, Sweden
5 Fertility Center, Malmö University Hospital, Lund University, Malmö, Sweden

* To whom correspondence should be addressed. E-mail: jakob.eberhard{at}kir.mas.lu.se.


  Abstract

BACKGROUND: Testicular cancer (TC) patients have a high survival rate, and the question of post-therapy recovery of sperm production and its dependence on genetic predisposition is of major interest. METHODS: Ejaculates were obtained from 112 TC patients at one or more of the following time points: post-orchidectomy, or 6, 12, 24, 36 and 60 months post-therapy. The lengths of the androgen receptor (AR) function modulating CAG and GGN repeats in leukocyte DNA were also analysed. RESULTS: No significant decrease in sperm concentration was seen in men who received 1-2 cycles of adjuvant chemotherapy (ACT). Radiotherapy (RT) or more than two cycles of chemotherapy (HCT) caused an initial decline in sperm concentration, which returned to pre-treatment levels 2-5 years after therapy. In the HCT group, sperm concentration 12-24 months post-treatment (T12-24) was inversely correlated with CAG length ({rho} = -0.72, P = 0.03). The type of treatment, but not the concentration at T0, was an independent predictor of sperm concentration at T6 (P < 0.0005) and T12-24 (P = 0.004). CONCLUSION: ACT did not induce a significant decline in sperm concentration. After HCT and RT, a significant reduction of sperm concentration was observed, recovering to pre-treatment levels 2-5 years post-treatment. In HCT-treated patients, the AR CAG length influenced the recovery of spermatogenesis.

Key words: Key words: androgen receptor/chemotherapy/radiotherapy/semen quality/testicular cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
T. Tandstad, O. Dahl, G. Cohn-Cedermark, E. Cavallin-Stahl, U. Stierner, A. Solberg, C. Langberg, R. M. Bremnes, A. Laurell, H. Wijkstrom, et al.
Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program
J. Clin. Oncol., May 1, 2009; 27(13): 2122 - 2128.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. Eberhard, O. Stahl, M. Cwikiel, E. Cavallin-Stahl, Y. Giwercman, E. C. Salmonson, and A. Giwercman
Risk factors for post-treatment hypogonadism in testicular cancer patients.
Eur. J. Endocrinol., April 1, 2008; 158(4): 561 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
O. Stahl, J. Eberhard, K. Jepson, M. Spano, M. Cwikiel, E. Cavallin-Stahl, and A. Giwercman
Sperm DNA integrity in testicular cancer patients
Hum. Reprod., December 1, 2006; 21(12): 3199 - 3205.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.